You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Role of Smac/DIABLO in cancer progression
|
|---|---|
| Published in |
Journal of Experimental & Clinical Cancer Research, September 2008
|
| DOI | 10.1186/1756-9966-27-48 |
| Pubmed ID | |
| Authors |
Gustavo Martinez-Ruiz, Vilma Maldonado, Gisela Ceballos-Cancino, Juan P Reyes Grajeda, Jorge Melendez-Zajgla |
| Abstract |
Second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO) is a proapoptogenic mitochondrial protein that is released to the cytosol in response to diverse apoptotic stimuli, including commonly used chemotherapeutic drugs. In the cytosol, Smac/DIABLO interacts and antagonizes inhibitors of apoptosis proteins (IAPs), thus allowing the activation of caspases and apoptosis. This activity has prompted the synthesis of peptidomimetics that could potentially be used in cancer therapy. For these reasons, several authors have analyzed the expression levels of Smac/DIABLO in samples of patients from different tumors. Although dissimilar results have been found, a tissue-specific role of this protein emerges from the data. The objective of this review is to present the current knowledge of the Smac/DIABLO role in cancer and its possible use as a marker or therapeutic target for drug design. |
Mendeley readers
The data shown below were compiled from readership statistics for 132 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 3 | 2% |
| United States | 1 | <1% |
| Poland | 1 | <1% |
| France | 1 | <1% |
| Unknown | 126 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 27 | 20% |
| Student > Bachelor | 23 | 17% |
| Researcher | 18 | 14% |
| Student > Master | 18 | 14% |
| Student > Doctoral Student | 10 | 8% |
| Other | 14 | 11% |
| Unknown | 22 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 37 | 28% |
| Biochemistry, Genetics and Molecular Biology | 33 | 25% |
| Medicine and Dentistry | 18 | 14% |
| Chemistry | 6 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Other | 9 | 7% |
| Unknown | 24 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 April 2021.
All research outputs
#1,811,223
of 25,374,647 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#61
of 2,378 outputs
Outputs of similar age
#4,703
of 99,325 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#1
of 9 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,378 research outputs from this source. They receive a mean Attention Score of 4.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 99,325 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them